Figure 3.
Antiproliferative measurements of heterocyclic ruthenium(III) complexes graphs [2,3,4], parthenolide [D] in A–C representing cell viability charts for the corresponding Ru(III) complexes against the selected cancer cell lines. (A) Human renal cancer cell (TK-10); (B) Human melanoma cancer cell (UACC-62); (C) Human breast cancer cell (MCF-7).